Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: Implication for reverse cholesterol transport

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 10, 1997, Pages 2020-2028

  Jin, Fu You ^a   Kamanna, Vaijinath S ^a   Kashyap, Moti L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Hepatic HDL uptake; Metabolism

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID;

ANGIOCARDIOGRAPHY; ANTIBODY AFFINITY; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL;

EID: 0031442321     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.10.2020     Document Type: Article

References (42)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558-559.
2. Parsons WB, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. Arch Intern Med. 1959;103:783-790.
3. Galbraith PA, Pevry WF, Beamish RE. Effect of nicotinic acid on serum lipids in normal and atherosclerotic subjects. Lancet. 1959;1:222-223.
4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease: the Coronary Drug Project. JAMA. 1975;231:360-381.
5. Carlson LA, Danielson M, Ekberg I, Klintemar B, Rosenhamer G. Reduction of myocardial reinfarction by combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977;28:81-86.
6. Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglyceride in man. J Lipid Res. 1981;22:24-36.
7. Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F. Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy. 1988;8:287-294.
8. Carlson LA. The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man: drugs affecting lipid metabolism. Adv Exp Med Biol. 1969;4:327-338.
9. Carlson LA, Olsson AG, Ballantyne D. On the rise in low density and high density lipoproteins in response to the treatment of hyperglyceridemia in type IV and type V hyperlipoproteinemias. Atherosclerosis. 1977;26:603-609.
10. 3 in hyperlipoproteinemia. J Intern Med. 1990;228:151-157.
11. Johansson J, Carlson LA. The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidemic subjects. Atherosclerosis. 1990;83:207-216.
12. Gray DR, Morgan TR, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121:252-258.
13. Superko HR, Williams FT, Alderman EL. Differential effect on HDL of niacin and resin in LDL subclass pattern A and B subjects. Circulation. 1993;88:2072A. Abstract.
14. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
15. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
16. Kashyap ML. Effects of drugs on HDL apoprotein metabolism. In Miller NE, ed. High Density Lipoproteins and Atherosclerosis, II. New York, NY: Elsevier Science Publishing Co; 1989.
17. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res. 1985;39:1-8.
18. Canner PL, Berge KG, Wanger NK. Fifteen-year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
19. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Carhin-Hemphill L. Beneficial effects of combined colestipol therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
20. Brown G, Albers JJ, Fisher LF. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
21. Blum CB, Levy RI, Eisenberg S, Hall M III, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977;60:795-807.
22. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63:858-867.
23. Zannis VI, Breslow JL, San Giacomo TR, Aden DP, Knowles BB. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry. 1981;20:2089-2096.
24. Thrift R, Forte TM, Cahoon BE, Shore VG. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. J Lipid Res. 1986;27:236-250.
25. Jin FY, Kamanna VS, Dhillon KS, Kashyap ML. Effect of niacin on high density lipoprotein apoA-I metabolism by human hepatocytes (Hep G2). J Invest Med. 1995;43:301A. Abstract.
26. Havel RJ, Eder HA, Bragdon JH. The distribution and characterization of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
28. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. J Biol Chem. 1984;12201-12209.
29. Rothwell TC, Kamanna VS, Jin FY, Koren E, Foley T, Kashyap ML. Characterization of a monoclonal antibody (HB-22) and development of an enzyme-linked immunosorbent assay for human apolipoprotein AI. Clin Chem. 1995;41:1150-1158.
30. Amarasuriya RN, Gupta AK, Given M, Horng YC, Maeda T, Kashyap ML. Ethanol stimulates apolipoprotein AI secretion by human hepatocytes: implications for a mechanism for atherosclerosis protection. Metabolism. 1992;41:827-832.
31. McFarlane AS. Efficient trace-labelling of proteins with iodine. Nature. 1958;182:53.
32. Shepherd J, Gotto AM, Taunton OD, Claslake MJ, Farish E. The in vitro interaction of human apolipoprotein AI and high density lipoproteins. Biochim Biophys Acta. 1977;489:486-501.
33. Tollefson JH, Albers JJ. Isolation, characterization, and assay of plasma lipid transfer proteins. Methods Enzymol. 1986;129:797-816.
34. Rinninger F, Pittman RC. Regulation of selective uptake of high-density lipoprotein-associated cholesteryl esters in human fibroblasts and Hep G2 hepatoma cells. J Lipid Res. 1988;29:1179-1194.
35. Fielding CJ, Fielding PE. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci USA. 1981;78:3911-3914.
36. Rothblatt GH, Bamberger M, Phillips MC. Reverse cholesterol transport. In: Colowich SP, Kaplan NO, eds.: Methods in Enzymology. Orlando, Fla: Academic Press; 1986:628-644.
37. Selam JL, Kashyap ML, Gupta AK, Turner D, Wong ND, Lozano JL, Charles MA. Alteration in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism. 1994;43:665-669.
38. Gupta AK, Ross EA, Myers JN, Kashyap ML. Increased reverse cholesterol transport in athletes. Metabolism. 1993;42:684-690.
39. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
40. Brown T. Analysis of RNA by Northern and slot blot hybridization. In: Ausubel FM, eds. Current Protocols in Molecular Biology. Brooklyn, NY: John Wiley & Sons; 1993:4.9.1-4.9.14.
41. Miller GJ, Miller NE. Plasma high density lipoprotein concentration of ischemic heart disease. Lancet. 1975;1:16-19.
42. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hully SB. HDL cholesterol and other lipids in coronary heart